Can changing carb sources help tame blood sugar swings in type 1 diabetes?

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Participants who agree to participate in the study and provide written informed consent; 2. Diagnosed with type 1 diabetes mellitus according to the ADA 2024 criteria; 3. Aged 18 to 70 years, inclusive; 4. Receiving exogenous insulin therapy with a stable treatment regimen for at least 2 months before enrollment (the type of insulin should remain unchanged, while the dose may be adjusted according to blood glucose levels); 5. Body mass index (BMI) between 18.0 and 25.0 kg/m², inclusive; 6. Glycated hemoglobin A1c (HbA1c) \<11%. Exclusion Criteria: 1. Type 1 diabetes mellitus in the honeymoon phase; 2. Pregnant or breastfeeding women, or women for whom pregnancy cannot be ruled out; 3. Patients who are vegetarians or are undergoing weight loss; 4. Patients who are users of oral hypoglycemic drugs (alpha-glucosidase inhibitors, DPP-4 inhibitors, etc.); 5. Use of glucocorticoids within 30 days before enrollment; 6. History of severe food allergy; 7. Patients with acute complications such as diabetic ketoacidosis (DKA) or hyperosmolar hyperglycemic state (HHS) within the previous 6 months; 8. Patients with gastroparesis, inflammatory bowel disease or other complications; 9. Patients with macroalbuminuria (albumin-to-creatinine ratio \> 34 mg/mmol) or renal insufficiency (creatinine \> 200 μmol/L); 10. Patients with uncontrolled hyperthyroidism or hypothyroidism (Uncontrolled hyperthyroidism is defined as abnormal TSH and FT4. Uncontrolled hypothyroidism is defined as TSH \> 10 mIU/L.); 11. History of heart disease, coronary artery disease or arrhythmia; 12. Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) \>3 times the upper limit of normal; 13. History of malignant tumors; history of tumors or surgery affecting digestion or nutrient absorption. Eligibility of participants with a history of benign tumors will be determined by the investigator; 14. Patients with other uncontrolled immune system diseases or uncontrolled infections; 15. Alcohol abuse, drug abuse, mental disorders, or other conditions unsuitable for study participation; 16. Any disease or condition that, in the investigator's judgment, may interfere with study participation or evaluation.